PharmaBlock Appointed David Chen as CFOr &Head of CDMO Business
PharmaBlock Wins ACS CMO Green Chemistry Award For Second Straight Year
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.
NANJING, China, Dec. 25, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced the successful attainment of Energy Management System Certification (ISO 50001:2018) for its headquarters and R&D center in Nanjing, as well as its manufacturing facilities in Zhejiang and Shandong, China. This achievement illustrates PharmaBlock's ongoing dedication to lean operations, energy efficiency, and sustainable development.
NANJING, China, Dec. 8, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has officially joined the United Nations Global Compact (UNGC), which not only affirms PharmaBlock's longstanding commitment to social responsibility but also signifies its dedication to implementing the ESG principles and contributing to achieving the global sustainable development goals.
NANJING, China, March 28, 2023 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CDMO company focusing on innovative chemistry and low-carbon manufacturing, announced today that it has been selected as the winner of the 2023 CMO Excellence in Green Chemistry Award by the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (GCI PR). This award honors and confirms PharmaBlock's commitment to green chemistry and its achievement in developing innovative solutions for sustainable development in the pharmaceutical industry.
PharmaBlock, a global CDMO focused on innovative chemistry and low-carbon manufacturing, opened a new R&D facility in West Chester, PA. The facility expands the company's footprint in the U.S. and enables more efficient process R&D services and fast delivery of clinical-stage GMP projects to global partners.
NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory Affairs, responsible for corporate quality management and regulatory affairs.
Former senior vice president of quality, Dr. Wenfang Miao, has been appointed as PharmaBlock’s chief executive officer.